ArticleCureus2026
Implication of Post-Induction Minimal Residual Disease in the Management of Pediatric Acute Lymphoblastic Leukemia in a Resource-Limited Setting.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimal residual disease (MRD) measurement in pediatric acute lymphoblastic leukemia (ALL) is the most powerful tool for treatment response assessment.
objectiveThis study aims to assess the implications of post-induction Day 29 MRD evaluation in the management of pediatric ALL within a resource-limited setting and its correlation with interim Day 8/15 bone marrow assessment. MATERIALS AND
methodsA prospective analytical study was conducted at the pediatric hematology oncology department from January 1, 2022, to December 31, 2022. Flowcytometry-based newly diagnosed ALL patients aged 1-16 years were included. MRD assessment on Day 29 of induction and interim bone marrow evaluations on Day 8/15 were performed according to the UKALL-2019 protocol.
resultsOut of 578 patients, 407 (70.4%) were males, and 171 (29.6%) were females. The predominant age group was 5-10 years, including 324 (56.0%) patients. Flow cytometry revealed pre-B ALL in 468 (81.0%) and pre-T ALL in 110 (19.0%). High-risk patients receiving four-drug induction numbered 379 (65.6%), while 199 (34.4%) were standard risk. Interim bone marrow response was M2 in 502 (86.9%) and M3 in 73 (12.6%). Post-induction Day 29 MRD was < 0.01% (negative) in 495 (85.6%) patients who continued the same regimen, and >0.01% (positive) in 83 (14.4%) requiring treatment escalation. Among those with M3 interim marrow response, 42 (7.3%) were high-risk and MRD-positive. Induction mortality occurred in 32 (5.5%) patients, and treatment abandonment occurred in 46 (8.0%).
conclusionOur study has demonstrated significant induction remission response in ALL by achieving negative MRD, which correlates strongly with interim bone marrow assessment, proposing Day 29 MRD as a single best cost-effective tool for response evaluation in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.